玻璃体腔注射雷珠单抗治疗病理性近视脉络膜新生血管被引量：6

Efficacy of intravitreal Ranibizumab injection for choroidal neovascularization secondary to pathologic myopia

导出

摘要目的：观察玻璃体腔注射雷珠单抗治疗病理性近视脉络膜新生血管（CNV）的临床疗效和安全性。方法：回顾分析临床确诊为病理性近视CNV患者24例25眼,所有患者行ETDRS视力表检查、前置镜下眼底检查、荧光素眼底血管造影（FFA）、吲哚菁绿血管造影（ICGA）、光学相干断层扫描（OCT）检查。所有患者按照常规内眼手术操作要求玻璃体腔内注射10mg/m L雷珠单抗0.05m L,随访4~10mo。观察比较治疗前后最佳矫正视力（BCVA）、黄斑中心凹视网膜厚度（CMT）。结果：所有患者均未出现与治疗相关的局部和全身并发症。平均治疗次数为1.52次。治疗前最佳矫正视力（BCVA）平均23.93±12.46个字母;末次随访BCVA平均40.63±7.25个字母,较治疗前提高14.27±9.36个字母,差异有统计学意义（t=5.74,P〈0.05）。治疗前CMT平均363.47±119.62μm,末次随访平均CMT为190.31±37.02μm,较治疗前下降72.82±60.57μm,差异有统计学意义（t=3.96,P〈0.05）。结论：玻璃体腔注射雷珠单抗治疗病理性近视CNV是安全有效的,有利于提高患者视力,减轻视网膜水肿,停止或减少病灶的渗漏。 AIM：To observe the efficacy and safety of intravitreal Ranibizumab injection in patiens with choroidal neovascularization（CNV） secondary to pathologic myopia.·METHODS：In this retrospective and comparative study,24 patients（25 eyes） with CNV secondary to pathologic myopia were enrolled.All patients were assessed by examinations of ETDRS visual acuity chart,preplacedmirror ophthalmoscopy,fundus fluorescein angiography（FFA）,indocyanine green angiography（ICGA） and optical coherence tomography（OCT）.Patiens received intravitreally injected ranibizumab 0.5mg（0.05mL）.Treatments were repeated if the follow-up indicated that it was necessary.The follow-up periods were 4~10mo.Best corrected visual acuity（BCVA）,central macular thickness（CMT） and leakage of CNV before and after the treatment were compared.·RESULTS：No local or systemic complications occurred in any patients during the treatment or follow-up.The average time of injection was 1.52.The mean BCVA was23.93±12.46 letters before the therapy.In the last followup,the mean BCVA was 40.63±7.25 letters,improved by14.27 ± 9.36 letters and the difference was statically significant（t=5.74,P0.05）.The mean CMT was 363.47±119.62μm before treatments and 190.31±37.02μm after treatments which was 72.82±60.57μm less than the pretreatment values and the difference was statically significant（t=3.96,P0.05）.·CONCLUSION：Intravitreal ranibizumab injection for CNV secondary to pathologic myopia is safe and effective,and this treatment can improve visual acuity,reduce retina edema and leakage of CNV.

作者崔丽红杨智徐丽

机构地区中国辽宁省沈阳市第四人民医院眼科

出处《国际眼科杂志》 CAS 2016年第3期526-528,共3页 International Eye Science

关键词脉络膜新生血管化药物疗法近视退行性抗体单克隆 choroidal neovascularization drug therapy myopia degenerative antibodies monoclonal

分类号 R778.11 [医药卫生—眼科]

引文网络
相关文献

参考文献10

1Ikuno Y,Jo Y,Hamasaki T,et al.Ocular risk factors for choroidal neovascularization in pathologic myopia. Invest Ophthalmol Vis Sci,2010;51(7):3721-3725.
2朱丹,金子夜,陶勇.玻璃体腔注射贝伐单抗与光动力疗法治疗病理性近视脉络膜新生血管疗效的meta分析[J].中华眼底病杂志,2014,30(5):509-513. 被引量：5
3Tano Y.Pathologic myopia:where are we now? Am J Ophthalmol,2002;134(5):645-660.
4Monés JM, Amselem L, Serrano A,et al.Intravitreal ranibizumab for choroidal neovascularization secondary to pathologic myopia:12-month results. Eye,2009;23(6):1275-1280.
5Tong JP, Chan WM, Liu DT, et al. Aqueous humor levels of vascular endothelial growth factor and pigment epithelium-derived factor in polypoidal choroidal vasculopathy and choroidal neovascularization. Am J Ophthalmol,2006;141(3):456-462.
6Gharbiya M,Allievi F,Conflitti S,et al.Intravitreal bevacizumab for treatment of myopic choroidal neovascularization:the second year of a prospective study. Clin Ter,2010;161(3):e87-93.
7Milani P, Massacesi A, Ciaccia S, et al.Only first intravitreal bevacizumab injection achieves statistically significant visual improvement in naive myopic choroidal neovascularization. Clin Ophthalmol,2012;6:1885-1894.
8Hayashi K, Ohno-Matsui K, Shimada N, et al.Intravitreal bevacizumab on myopic choroidal neovascularization that was refractory to or had recurred after photodynamic therapy. Graefes Arch Clin Exp Ophthalmol,2009;247(5):609-618.
9Gharbiya M,Allievi F,Mazzeo L,et al.Intravitreal bevacizumab treatment for choroidal neovascularization in pathologic myopia:12-month results. Am J Ophthalmol,2009;147(1):84-93.
10Silva RM,Ruiz-Moreno JM,Rosa P,et al.Intravitreal ranibizumab for myopic choroidal neovascularization:12-month results. Retina,2010;30(3):407-412.

二级参考文献24

1Neelam K,Cheung CM,Ohno-Matsui K,et al.Choroidal neovascularization in pathological myopia[J].Prog Retin Eye Res,2012,31:495-525.
2Chan WM,Lai TY,Chan KP,et al.Changes in aqueous vascular endothelial growth factor and pigment epithelial-derived factor levels following intravitreal bevacizumab injections for choroidal neovascularization secondary to age-related macular degeneration or pathologic myopia[J].Retina,2008,28:1308-1313.
3Mandal S,Venkatesh P,Sampangi R,et al.Intravitreal bevacizumab (Avastin) as primary treatment for myopic choroidal neovascularization[J].Eur J Ophthalmol,2007,17:620-626.
4Yamamoto I,Rogers AH,Reichel E,et al.Intravitreal bevacizumab (Avastin) as treatment for subfoveal choroidal neovascularisation secondary to pathological myopia[J].Br J Ophthalmol,2007,91:157-160.
5Gharbiya M,Giustolisi R,Allievi F,et al.Choroidal neovascularization in pathologic myopia.:intravitreal ranibizumab versus bevacizumab-a randomized controlled trial[J].Am J Ophthalmol,2010,149:458-464.
6Sakaguchi H,Ikuno Y,Gomi F,et al.Intravitreal injection of bevacizumab for choroidal neovascularisation associated with pathological myopia[J].Br J Ophthalmol,2007,91:161-165.
7Arias L,Planas N,Prades S,et al.Intravitreal bevacizumab (Avastin) for choroidal neovascularisation secondary to pathological myopia:6-month results[J].Br J Ophthalmol,2008,92:1035-1039.
8Jadad AR,Moore RA,Carroll D,et al.Assessing the quality of reports of randomized clinical trials.:is blinding necessary?[J].Control Clin Trials,1996,17:1-12.
9Baba T,Kubota-Taniai M,Kitahashi M,et al.Two-year comparison of photodynamic therapy and intravitreal bevacizumab for treatment of myopic choroidal neovascularisation[J].Br J Ophthalmol,2010,94:864-870.
10Hayashi K,Ohno-Matsui K,Teramukai S,et al.Comparison of visual outcome and regression pattern of myopic choroidal neovascularization after intravitreal bevacizumab or after photodynamic therapy[J].Am J Ophthalmol,2009,148:396-408.